Exploring the performance of Escherichia coli outer membrane vesicles as a tool for vaccine development against Chagas disease

VÁZQUEZ, MARÍA ELISA; MESÍAS, ANDREA CECILIA; ACUÑA, LEONARDO; SPANGLER, JOSEPH; ZABALA, BRENDA; PARODI, CECILIA; THAKUR, MEGHNA; OH, EUNKEU; WALPER, SCOTT ALLAN; BRANDÁN, CECILIA PÉREZ

MEMóRIAS DO INSTITUTO OSWALDO CRUZ.

FUNDACO OSWALDO CRUZ

Lugar: Rio de Janeiro; Año: 2023 vol. 118 p. 1 - 12

0074-0276

BACKGROUND Vaccine development is a laborious craftwork in which at least two main components must be defined: a highly immunogenic antigen and a suitable delivery method. Hence, the interplay of these elements could elicit the required immune response to cope with the targeted pathogen with a long-lasting protective capacity. OBJECTIVES Here we evaluate the properties of Escherichia coli spherical proteoliposomes — known as outer membrane vesicles (OMVs) — as particles with natural adjuvant capacities and as antigen-carrier structures to assemble an innovative prophylactic vaccine for Chagas disease. METHODS To achieve this, genetic manipulation was carried out on E. coli using an engineered plasmid containing the Tc24 Trypanosoma cruzi antigen. The goal was to induce the release of OMVs displaying the parasite protein on their surface. FINDINGS As a proof of principle, we observed that native OMVs — as well as those carrying the T. cruzi antigen — were able to trigger a slight, but functional humoral response at low immunization doses. Of note, compared to the non-immunized group, native OMVs-vaccinated animals survived the lethal challenge and showed minor parasitemia values, suggesting a possible involvement of innate trained immunity mechanism. MAIN CONCLUSION These results open the range for further research on the design of new carrier strategies focused on innate immunity activation as an additional immunization target and venture to seek for alternative forms in which OMVs could be used for optimizing vaccine development.